School’s out for those not connected
Online education during the pandemic blacks out marginalised students in Odisha’s rural districts
Days after AstraZeneca resumed trials on the AZ-Oxford University vaccine candidate against Covid-19, clinical trials will resume in India as well. The Drug Controller General of India (DCGI) has given its green signal to Serum Institute of India to resume trials on the Covid-19 vaccine candidate, with greater attention on screening and monitoring for adverse events.
The vaccine trial had been paused in India after AZ had done the same globally, following an adverse event that was reported in one trial participant in the United Kingdom.
AZ resumed trials after the UK’s Medicines Health Regulatory Authority (MHRA) confirmed it was safe to do so.
However, trials on the AZ-Oxford candidate are yet to resume in the United States, and reports suggest that US authorities were investigating the adverse event that had been reported in the UK. A source-based report indicated that approvals to resume the trial may not come in till mid next week.
Calls for transparency
AZ and Oxford University have not revealed the nature of the adverse event, though reports have linked it to transverse myelitis, an inflammation of the spinal cord that could lead to paralysis, bladder, bowel dysfunction. In fact, voices from the clinical research community have called for greater transparency on trial details, given the public funds invested and government support behind fast-tracking the trial.
The company’s chief had briefed the investor community after the adverse event had required halting the vaccine trial. But global scientific voices have urged AZ to be more public with details on the trial and adverse event in the interest of greater trust in clinical research, especially since timelines on the vaccine-development have been shortened. Less transparency could lead to people having less confidence in taking the vaccine, they cautioned.
Serum to resume
About 100 people have already been given the first shot of the two-dose vaccine, and the trial had been paused for seven days as the DCGI wanted safety to be reviewed, a person familiar with the development told Business Line. The AZ adverse-event-linked pause coincided with this period, the person said.
The DCGI approval to resume trials echoes the MHRA’s directive on greater scrutiny and screening, the source said. The second dose of the vaccine-probable would be given after a 28-period gap from the first shot. And 28 days after the second dose, blood samples of the volunteers in the trial would be screened.
A total of 1,700 persons would be recruited for the trial from 17 centres, the source said, adding that the trial would take about three to four months.